EQS-News: Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences

Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences

Kensington, MD, USA and Munich/Martinsried, Germany, September 22, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced that the company will participate in a variety of events this fall in both the U.S. and Europe.

Partnering and Investor Events

LSX Congress USADate: September 23 - 24Location: Boston, MA, USA

H.C. Wainwright Biotech on TapDate: October 1- 3Location: Munich, Germany

26th Annual Biotech in Europe Forum | #Sachs_BEFDate: October 7 - 8Location: Basel, SwitzerlandCompany Presentation: October 7, 2:45 pm (CEST), Track B, Room "Ballroom"Panel: Neuroscience Innovation panel | October 7; 4:35 pm (CEST)Panelist & Presenter: Alexander Gebauer, MD, PhD, Co-Founder and Executive Chairman of Galimedix

BioFutureDate: October 27 - 28Location: New York, NY, USACompany Presentation: not yet announcedPanel: Spotlight Panel 4B - Rewiring Minds: Breakthroughs in Brain & CNS Health | October 28; 10:00 am (EDT)Panelist & Presenter: Alexander Gebauer, MD, PhD, Co-Founder and Executive Chairman of Galimedix

BIO-EuropeDate: November 9 - 11Location: Cologne, Germany

Scientific Conferences

26th EURETINA CongressDate: October 1-4Location: Vienna, AustriaSeveral oral presentations and e-posters related to Phase 2 eDREAM study in geographic atrophyMore information on the data presented at Euretina can be found here.

American Academy of Ophthalmology Annual MeetingDate: October 9 - 12Location: New Orleans, LA, USA

Clinical Trials on Alzheimer's Disease (CTAD) ConferenceDate: November 16 - 19Location: Boston, MA, USAPoster Title: SAPHARY Phase 2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer's disease

Attendees interested in meeting with the Galimedix team can schedule a meeting via the respective conference's partnering system, e-Mail or LinkedIn.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease - Galimedix’s initial areas of focus. For more information, visit www.galimedix.com and follow us on LinkedIn.